## 3 Methods
### Analysed Variables

Table 2: _Cont._  
\begin{table}
\begin{tabular}{c c c} \hline \hline \multicolumn{1}{c}{**Neoadjuvant Hormone**} & \multirow{2}{*}{**References**} & \multicolumn{2}{c}{**Number of Trials**} \\
**Depritation Therapy** & & **Where It Was Used (\(n\))** \\ \hline Abiraterone & [20, 21, 22, 23, 24, 25, 26, 27, 28, 29] & 10 \\ \hline Abiraterone or leuprolide & [30] & 1 \\ \hline Abiraterone, apalutamide or & [31, 32, 33, 34] & 4 \\ leuprolide & [35, 36, 37, 38, 39, 40] & 6 \\ \hline Bicalutamide & [41] & 1 \\ \hline Bicalutamide and leuprorelin & [42, 43, 44] & 3 \\ \hline Bicalutamide, Degarelik, goserelin, & [24] & 1 \\ leuprorelin, tritprotein & & \\ \hline Bilateral orchiectomy or LHRH & [30, 31, 32, 42, 43, 45, 46, 47, 48, 49, 50] & 11 \\ agonist or LHRH antagonist & [35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50] & 11 \\ \hline Darolutamide & [51, 52, 23] & 4 \\ \hline Degarelik or goserelin or leuprolide & [24, 47] & 2 \\ \hline Docetaxel, Enzalutamide & [53, 54] & 2 \\ \hline Flutamide & [55, 56] & 2 \\ \hline Goserelin or Degarelik or leuprolide & [47] & 1 \\ or tritprotein & & \\ \hline Ketoconazole & [57, 58] & 1 \\ \hline Leuprolide & [47, 59] & 2 \\ \hline Letrozole & [60, 61] & 2 \\ \hline Relugolix & [45] & 1 \\ \hline Talazoparib, Enzalutamida & [62] & 1 \\ \hline Testosterone & [24, 63, 64] & 3 \\ \hline The choice of the physician or & [20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,  
specification of ADT (\(n=22\)), abiraterone or enzalutamide (\(n=11\)) and abiraterone (\(n=8\)). In the multivariate analysis, no differences were found between the different modalities of ADT that could determine clinical results of superiority, equality, or inferiority over the standard treatments for prostate cancer. \begin{table}
\begin{tabular}{c c c} \hline \hline
**Adjuvant Hormonal Deprivation** & **References** &
\begin{tabular}{c} **Number of Trials** \\ **Where It Was Used (\(n\))** \\ \end{tabular} \\ \hline Abiraterone & [73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83] & \(11\) \\ \hline Abiraterone or apalutamide & [80; 84; 85; 86; 87; 88; 89] & \(7\) \\ \hline Abiraterone or apalutamide & [90] & \(1\) \\ or leuprolide & [91] & \(1\) \\ \hline Abiraterone or apalutamide & [92] & \(1\) \\ or degarelix & [91] & \(1\) \\ \hline Abiraterone or bicaltumamide & [92; 93] & \(2\) \\ or leuprorelin & [94; 95; 96; 97; 98; 99; 100; 101; 102; 103; 104; 105; 106; 107; 108; 109; 100; 101; 102; 104; 105; 107; 108; 109; 101; 103; 104; 106; 107; 108; 109; 100; 101; 104; 105; 109; 101; 102; 103; 105; 106; 107; 108; 109; 101; 105; 107; 109; 108; 101; 109; 100; 101; 105; 101; 106; 107; 108; 109; 101; 105; 101; 106; 107; 109; 101; 108; 109; 102; 101; 103; 105; 107; 109; 101; 101; 105; 108; 101; 109; 103; 101; 101; 104; 105; 106; 107; 109; 108; 109; 110; 111; 111; 112; 113; 114] & \(7\) \\ \hline Abiraterone or leuprorelin & [115] & \(1\) \\ \hline Apalutamide or leuprorelin & [79; 81; 90; 116; 117] & \(5\) \\ \hline Bicalutamide & [107] & \(1\) \\ \hline Cabazitaxel & [82; 112] & \(2\) \\ \hline Docetaxel & [88; 93; 117; 118] & \(4\) \\ \hline Enzalutamide & [90; 98; 102; 104; 105; 108; 109; 119; 120; 121; 122; 123; 124; 125; 126; 127; 128; 129; 130] & \(19\) \\ \hline Leuprorelin & [131; 132] & \(2\) \\ \hline Leuprorelin or testosterone & [74; 105; 110; 111] & \(4\) \\ \hline TCR253 & [133] & \(1\) \\ \hline The choice of the physician & [92; 134; 135; 136; 137; 138; 139] & \(8\) \\ or institution & [140; 141; 142; 143] & \(4\) \\ \hline \hline \end{tabular}
\end{table} 
Table 4: Hormonal deprivation therapies used in adjuvant trials.